- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03071042
A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Hongming Pan, MD
- Número de telefone: +86-13605716662
Locais de estudo
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Recrutamento
- Sir Run Run Shaw Hospital
-
Contato:
- Pan Hongming, MD
- Número de telefone: +86-13605716662
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
- Age: ≥18 years old;
Locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma ) patients confirmed by radiologic imaging or endoscopy tests, who had failed in first-line treatments;
- First-line treatment should be 5-Fu combined with platinum based regimen;
- Adjuvant/neoadjuvant chemotherapy should be defined as the first-line treatment, if recurrence happened within 6 months after completion of 5-Fu and platinum based adjuvant/ neoadjuvant chemotherapy;
- Adjuvant/neoadjuvant chemotherapy history is allowed, if first-line treatment is applied more than 6 months later than prior treatments;
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure;
- ECOG Performance Status ≤1;
- Life expectancy shouldn't less than 16 weeks, since the first medicine application time;
Major organ function has to meet the following criteria (within 28 days before treatment):
- HB ≥9.0 g/dL
- ANC ≥1.5X109/L
- PLT ≥100x109/L
- Bilirubin ≤1.5 times the upper limit of normal (ULN)
- ALT (SGOT) and AST (SGPT) ≤2.5 × ULN, unless liver metastases; if any, the ALT and AST≤5 × ULN
- Serum Cr ≤ 1.5 x ULN
- Patients must have at least one assessable lesion (including measurable and/or immeasurable) by radiological imagine (CT/MRI);
Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 28 days before enrollment and the test result must be negative. Or menopause women, defined as follow:
- ≥1 year no menstruation, after abort exogenous hormone treatment
- Serum LH and FSH meet menopause criteria
- More than 1 year no menstruation for ovarian function failure induced by radiation therapy.
- More than 1 year no menstruation for menopause induced by chemotherapy
- Surgical sterilization accepted (hysterectomy or ovariectomy)
Exclusion Criteria:
- Involved in another on-going clinical trials;
- Accept more than one chemotherapy previously in advanced gastric cancer (except more than 6 months from adjuvant/neoadjuvant treatment);
- Prior taxane treatment (including Paclitaxel and Docetaxel);
- Prior VEGFR inhibitor treatment (including Sorafenib and Sunitinib);
- History of another malignancy within the last five years except cured nonmelanoma Skin cancer and carcinoma in situ of uterine cervix;
- Any factors that influence the usage of oral administration;
- History of the investigational agent treatment in 14 day prior to enroll in study (longer time period may be required which depends on drug characteristic);
- Accept any chemotherapy and radiotherapy (excluding Palliative radiotherapy) in 3 weeks prior to study (longer time period may be required which depends on drug characteristic);
- Poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class I; I-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class I cardiac dysfunction; Patients with positive urinary protein;
- Poor-controlled adverse events (excluding Alopecia) induced by tumor therapy (>class 1 CTCAE);
- History of intestinal obstruction or more than class 3 or 4 (CTCAE) gastrointestinal bleeding in 4 weeks prior to enroll in study;
- Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;
- Clinical evidence in central nervous system (CNS) and poor-controlled CNS metastasis (No necessary to confirm negative CNS metastasis by CT/MRI);
- Surgery within 2 weeks prior to enroll in study;
- History of significant and poor-controlled diseases or infection, in the opinion of investigators, may impact the safety of the patients of the study;
- Known history of human immunodeficiency, e.g. HIV positive;
- Known or suspected allergy to the investigational agent or any agent given in association with this trial;
- Pregnant or lactating patients.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Apatinib plus Docetaxel
Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed.
If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively.
This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
|
Apatinib Mesylate Tablets 425mg (500mg,675mg or 750mg) po.
qd continuous;
Outros nomes:
Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Tolerance profile of participants with treatment-related adverse events as assessed by CTCAE v4.0
Prazo: At least 4 weeks
|
At least 4 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Hongming Pan, MD, The Affiliated Sir Run Run Shaw Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por Tipo Histológico
- Neoplasias
- Carcinoma
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Moduladores de Tubulina
- Agentes Antimitóticos
- Moduladores de Mitose
- Inibidores de proteína quinase
- Docetaxel
- Apatinibe
Outros números de identificação do estudo
- Ahead-G306
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Apatinib
-
Peking Union Medical College HospitalConcluídoColangiocarcinoma | Neoplasia hepatobiliar | Câncer de Trato Biliar | BiomarcadorChina
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Ainda não está recrutandoCâncer Metastático do Trato Biliar | Câncer de Trato Biliar Localmente AvançadoChina
-
Second Affiliated Hospital, School of Medicine,...Ainda não está recrutando
-
Tianjin Medical University Cancer Institute and...RecrutamentoCarcinoma hepatocelular ressecávelChina
-
Hebei Medical University Fourth HospitalRecrutamento
-
Liang PengGuangzhou Virotech Pharmaceutical Co., Ltd.DesconhecidoCarcinoma hepatocelular avançado/metastático
-
Cancer Institute and Hospital, Chinese Academy...Jiangsu HengRui Medicine Co., Ltd.Ativo, não recrutandoCâncer de ovário recorrente resistente à platinaChina
-
Jiuda ZhaoSecond Hospital of Lanzhou UniversityRecrutamentoCâncer de intestino | Quimioterapia | ImunoterapiaChina